Bissera A. Pilicheva, Margarita I. Kassarova, Plamen I. Zagorchev and Yordanka I. Uzunova
Betahistine dihydrochloride is a histamine-like drug widely used in relieving the symptoms associated with Ménière’s syndrome. Pharmacokinetic studies of betahistine have demonstrated that it has a short plasma half-life of 3-4 hours. In such cases frequent administration of the drug is required in order to keep plasma concentration within the therapeutic range. However, this may lead to noncompliance and aggravate patients’ comfort. An advanced approach for achieving sustained release of drugs is their incorporation in microparticulate carriers. AIM: To design a sustained release microsphere formulation of betahistine providing reduced dose frequency and lower risk of side effects occurrence. MATERIALS AND METHODS: Betahistine-loaded chitosan microspheres were obtained via W/O emulsion solvent evaporation technique and were characterized for particle size, drug loading and entrapment efficiency. Drug release into phosphate buffer saline pH 7.4 was performed and dissolution profiles of the formulations were obtained. To study the mechanism of drug release from the microspheres the dissolution data was fitted to various mathematic models. RESULTS: Betahistine-loaded microspheres were produced with a high drug loading and entrapment efficiency. The microcarriers were spherical in shape with mean particle size of 3.82 μm to 7.69 μm. Betahistine release studies from the microspheres showed similar and slightly increasing dissolution profiles. The drug release proceeded in a controlled manner following Fickian diffusion. CONCLUSION: The obtained results suggest that betahistine-loaded chitosan microspheres prepared by solvent evaporation method are capable of sustained release of drugs and therefore can be used as drug delivery systems in the treatment of Ménière’s syndrome.
Robert-Alexandru Vlad, Lenard Farczadi, Silvia Imre, Adriana Daniela Ciurba, Nicoleta Todoran, Emoke Redai, Paula Antonoaea and Daniela Lucia Muntean
4. Pisanti S, Malfitano AM, Ciaglia E et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133-150.
5. Lucas CJ, Galettis P, Schneider J et al. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84:2477-2482.
6. Jalali SAM, Johnson WE. The Development of Cannabidiol as a Psychiatric Therapeutic: a Review of Its Antipsychotic Efficacy and Possible Underlying Pharmacodynamic Mechanisms. International Neuropsychiatric Disease Journal. 2013;1:113-147.
Danijela Tasic, Nebojsa Tasic, Dalibor Dragisic and Miroslav Mitrovic
1. Fatima S. et al., A review on importance of ACE inhibitors in clinical practice. Med. Res. Chron., 2014, 1 (1), 102-109.
2. Mancia G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul; 31(7): 1281-357.
3. Wiseman LR, McTavish D. Trandolapril. A review of its pharmacodynamic and pharmacokinetic
Irina Magdalena Dumitru, Roxana Carmen Cernat and S. Rugină
.L., Hadzic, T. & Kashuba, A.D. (2013). Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 52(11), 981-994
9. FDA approves new drug to treat HIV infection. (2013). Retrieved from http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm364744.html
10. Min, S., Song, I. & Borland, J. et al. (2010). Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 54, 254
Activity in Adult Rats: An in Vitro and in Vivo Comparison. Fundam App Toxicol 38 : 148-157.
Cochran RC. (2002). Appraisal of Risks from Nonoccupational Exposure to Chlorpyrifos. Reg Toxicol Pharmacol 35 : 105-121.
Cook TJ and Shenoy SS. (2003). Intestinal permeability of chlorpyrifos using the single-pass intestinal perfusion method in the rat. Toxicology 184 : 125-133.
El-Masri HA, Mumtaz MM and Yushak ML. (2004). Application of physiologically-based pharmacokinetic modeling to
Mahu Ştefania Corina, Hăncianu Monica, Agoroaei Luminiţa, Coman Băbuşanu Anda Cristina and Butnaru Elena
1. Katalin M. New therapeutic perspectives in hypertension treatment. Acta Medica Marisiensis. 2012; 58(2):124-130.
2. Xu T, Bao S, Geng P et al. Determination of metoprolol and its two metabolites in human plasma and urine by high performance liquid chromatography with fluorescence detection and its application in pharmacokinetics. J Chromatogr B. 2013;937:60-66.
3. Pujos E, Cren-Olive C, Paisse O, Flament-Waton M, Grenier-Loustalot MF. Comparison of the analysis of β-blockers by different techniques. J Chromatogr B. 2009
Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2: 274-302.
Cherry KE, Morton MR. Drug sensitivity in older adults: the role of physiologic and pharmacokinetic factors. Int J Aging Hum Dev 1989; 28: 159-74.
Linjakumpu T. Drug use among the home-dwelling elderly. Trends, polypharmacy, and sedation. Pridobljeno 12.5.2009 s spletne strani: http://herkules.oulu.fi/isbn9514271025/isbn9514271025.pdf
Mangoni AA, Jackson SH. Age
SW, Lai J, Porreca F, Vardanyan R, Hruby VJ. (2007). Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors. Bioorg Med Chem Lett 17: 2161-2165.
Lemmens H. (1995). Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia. Clin Pharmacokinet 29: 231-242.
Litchfi eld JTJr, Wilcoxon F. (1949). A simplifi ed method of evaluating dose-effect experiments. J Pharm Exp Ther 96: 99-113.
Mather LE. (1983). Clinical
Mariana A. Murdjeva, Emilia T. Milieva, Rumen S. Stefanov, Marian M. Draganov and Petko B. Krastev
Biology - Animal 2000;36:284-6.
10. Pavlova P. Quantitative assessment of fluorescence microscopic images. Automatics and Informatics. 2010;2:25-8 (Bulgarian).
11. Sinko PJ. Micromeritics. In: Sinko PJ (editor). Martin’s Physical Pharmacy and Pharmaceutical Sciences, 5th ed. Lippincott: Williams & Wilkins; 2006:533-40.
12. Ahmad MZ, Akhter S, Anwar M, et al. Colorectal cancer targeted Irinotecan-Assam Borarice starch based microspheres: a mechanistic, pharmacokinetic and biochemical investigation. Drug Dev Ind Pharm 2013